Skip to main content
Erschienen in: Supportive Care in Cancer 3/2011

01.03.2011 | Original Article

Patients’ views about causes and preferences for the management of cancer-related fatigue—a case for non-congruence with the physicians?

verfasst von: Christophe Luthy, Christine Cedraschi, Angela Pugliesi, Katie Di Silvestro, Beatrice Mugnier-Konrad, Elisabetta Rapiti, Anne-Francoise Allaz

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related fatigue (CRF) is frequently overlooked. Adherence to treatment guidelines may be related to the patient’s views about illness. This study aimed at exploring patients’ views about CRF and determining whether they are congruent with best practice treatments.

Methods

Data were collected in 160 consecutive patients hospitalized in a supportive care setting. Biological, clinical, and psychological variables were assessed using validated questionnaires. Patients were also asked to complete the Brief Fatigue Inventory (BFI) and a questionnaire investigating their main symptoms and views about CRF and its management.

Results

Patients were mainly men (60%); median age was 66 years. Various cancer diagnoses were represented; 17.5% had primary local diseases, 40% local recurrences, and 42.5% metastatic diseases. The majority of the patients experienced moderate or severe CRF (76.3%) on the BFI. Fatigue was the most frequently reported symptom (87.5%). Only anxiety, depression, and dimensions of quality of life were significantly related with CRF. Two thirds of the patients associated CRF with cancer-related morbidities. As for the best treatments, patients first stressed control of adverse effects. Over half of the patients were reluctant to report fatigue, mainly because they considered fatigue as an unavoidable side effect, but also because they feared a change towards less active/aggressive treatments.

Conclusion

Patients mostly consider that CRF must be tolerated. Guidelines emphasize activity enhancement strategies as beneficial. The patients’ preferences for rest rather than activity may be related to their high level of fatigue, which leads them to disregard activity as a possible treatment.
Literatur
1.
Zurück zum Zitat Mock V, Atkinson A, Barsevick A et al (2000) NCCN practice guidelines for cancer-related fatigue. Oncology 14:151–161PubMed Mock V, Atkinson A, Barsevick A et al (2000) NCCN practice guidelines for cancer-related fatigue. Oncology 14:151–161PubMed
4.
Zurück zum Zitat Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362:640–650PubMedCrossRef Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362:640–650PubMedCrossRef
5.
Zurück zum Zitat Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26:3886–3895PubMedCrossRef Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26:3886–3895PubMedCrossRef
6.
Zurück zum Zitat Lesage P, Portenoy RK (2002) Management of fatigue in the cancer patient. Oncology 16:373–381PubMed Lesage P, Portenoy RK (2002) Management of fatigue in the cancer patient. Oncology 16:373–381PubMed
7.
Zurück zum Zitat Flechtner H, Bottomley A (2003) Fatigue and quality of life: lessons from the real world. Oncologist 8:5–9PubMedCrossRef Flechtner H, Bottomley A (2003) Fatigue and quality of life: lessons from the real world. Oncologist 8:5–9PubMedCrossRef
8.
Zurück zum Zitat Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 98:1786–1801PubMedCrossRef Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 98:1786–1801PubMedCrossRef
9.
Zurück zum Zitat Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389–398PubMedCrossRef Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389–398PubMedCrossRef
10.
Zurück zum Zitat Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl 1):4–10PubMedCrossRef Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl 1):4–10PubMedCrossRef
11.
Zurück zum Zitat Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer fatigue forum. Ann Oncol 11:971–975PubMedCrossRef Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer fatigue forum. Ann Oncol 11:971–975PubMedCrossRef
12.
Zurück zum Zitat Minton O, Stone P, Richardson A, Sharpe M, Hotopf M (2008) Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 1:CD006704PubMed Minton O, Stone P, Richardson A, Sharpe M, Hotopf M (2008) Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 1:CD006704PubMed
13.
Zurück zum Zitat Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2:CD006145PubMed Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2:CD006145PubMed
14.
Zurück zum Zitat Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 1:CD006953PubMed Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 1:CD006953PubMed
15.
Zurück zum Zitat Donovan JL, Blake DR (1992) Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 34:507–513PubMedCrossRef Donovan JL, Blake DR (1992) Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 34:507–513PubMedCrossRef
16.
Zurück zum Zitat Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP (2005) Interventions for enhancing medication adherence. Cochrane Database Syst Rev, Issue 4 Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP (2005) Interventions for enhancing medication adherence. Cochrane Database Syst Rev, Issue 4
17.
Zurück zum Zitat Blank T, Graves K, Sepucha K, Llewellyn-Thomas H (2006) Understanding treatment decision making: contexts, commonalities, complexities, and challenges. Ann Behav Med 32:211–217PubMedCrossRef Blank T, Graves K, Sepucha K, Llewellyn-Thomas H (2006) Understanding treatment decision making: contexts, commonalities, complexities, and challenges. Ann Behav Med 32:211–217PubMedCrossRef
18.
Zurück zum Zitat Piguet V, Cedraschi C, Dumont P, Desmeules J, Allaz AF, Dayer P (2007) Patients’ representations of antidepressants: a clue to nonadherence? Clin J Pain 23:669–675PubMedCrossRef Piguet V, Cedraschi C, Dumont P, Desmeules J, Allaz AF, Dayer P (2007) Patients representations of antidepressants: a clue to nonadherence? Clin J Pain 23:669–675PubMedCrossRef
19.
Zurück zum Zitat Mendoza TR, Wang XS, Cleeland CS (1999) The rapid assessment of fatigue severity in cancer patients. Cancer 85:1186–1196PubMedCrossRef Mendoza TR, Wang XS, Cleeland CS (1999) The rapid assessment of fatigue severity in cancer patients. Cancer 85:1186–1196PubMedCrossRef
20.
Zurück zum Zitat Whitehead L (2009) The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage 37:107–128PubMedCrossRef Whitehead L (2009) The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage 37:107–128PubMedCrossRef
21.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
22.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 5:649–655CrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 5:649–655CrossRef
23.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
24.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef
25.
Zurück zum Zitat Razavi D, Delvaux N, Farvacques C, Robaye E (1989) Validation de la version française du HADS dans une population de patients cancéreux hospitalisés. Rev Psychol App 39:295–308 Razavi D, Delvaux N, Farvacques C, Robaye E (1989) Validation de la version française du HADS dans une population de patients cancéreux hospitalisés. Rev Psychol App 39:295–308
26.
Zurück zum Zitat Passik SD, Kirsh KL, Donaghy K, Holtsclaw E, Theobald D, Cella D, Breitbart W, Fatigue Coalition (2002) Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 24:481–493PubMedCrossRef Passik SD, Kirsh KL, Donaghy K, Holtsclaw E, Theobald D, Cella D, Breitbart W, Fatigue Coalition (2002) Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 24:481–493PubMedCrossRef
27.
Zurück zum Zitat Escalante CP (2003) Treatment of cancer-related fatigue: an update. Support Care Cancer 11:79–83PubMed Escalante CP (2003) Treatment of cancer-related fatigue: an update. Support Care Cancer 11:79–83PubMed
28.
Zurück zum Zitat Echteld MA, Passchier J, Teunissen S, Claessen S, de Wit R, van der Rijt CC (2007) Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer 43:1030–1036PubMedCrossRef Echteld MA, Passchier J, Teunissen S, Claessen S, de Wit R, van der Rijt CC (2007) Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer 43:1030–1036PubMedCrossRef
29.
Zurück zum Zitat Cella D (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology 20:25–28PubMed Cella D (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology 20:25–28PubMed
30.
Zurück zum Zitat Jacobsen PB, Garland LL, Booth-Jones M, Donovan KA, Thors CL, Winters E, Grendys E (2004) Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 28:7–18PubMedCrossRef Jacobsen PB, Garland LL, Booth-Jones M, Donovan KA, Thors CL, Winters E, Grendys E (2004) Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 28:7–18PubMedCrossRef
31.
Zurück zum Zitat Romito F, Montanaro R, Corvasce C, Di Bisceglie M, Mattioli V (2008) Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer 16:943–946PubMedCrossRef Romito F, Montanaro R, Corvasce C, Di Bisceglie M, Mattioli V (2008) Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer 16:943–946PubMedCrossRef
32.
Zurück zum Zitat Collins S, de Vogel-Voogt E, Visser A, van der Heide A (2008) Presence, communication and treatment of fatigue and pain complaints in incurable cancer patients. Patient Educ Couns 72:102–108PubMedCrossRef Collins S, de Vogel-Voogt E, Visser A, van der Heide A (2008) Presence, communication and treatment of fatigue and pain complaints in incurable cancer patients. Patient Educ Couns 72:102–108PubMedCrossRef
33.
Zurück zum Zitat Higginson IJ, Costantini M (2008) Dying with cancer, living well with advanced cancer. Eur J Cancer 44:1414–1424PubMedCrossRef Higginson IJ, Costantini M (2008) Dying with cancer, living well with advanced cancer. Eur J Cancer 44:1414–1424PubMedCrossRef
34.
Zurück zum Zitat Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447PubMedCrossRef Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447PubMedCrossRef
35.
Zurück zum Zitat Hay MC, Weisner TS, Subramanian S, Duan N, Niedzinski EJ, Kravitz RL (2008) Harnessing experience: exploring the gap between evidence-based medicine and clinical practice. J Eval Clin Pract 14:707–713PubMedCrossRef Hay MC, Weisner TS, Subramanian S, Duan N, Niedzinski EJ, Kravitz RL (2008) Harnessing experience: exploring the gap between evidence-based medicine and clinical practice. J Eval Clin Pract 14:707–713PubMedCrossRef
36.
Zurück zum Zitat Greenfield S, Kravitz R, Duan N, Kaplan SH (2007) Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120:S3–S9PubMedCrossRef Greenfield S, Kravitz R, Duan N, Kaplan SH (2007) Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120:S3–S9PubMedCrossRef
Metadaten
Titel
Patients’ views about causes and preferences for the management of cancer-related fatigue—a case for non-congruence with the physicians?
verfasst von
Christophe Luthy
Christine Cedraschi
Angela Pugliesi
Katie Di Silvestro
Beatrice Mugnier-Konrad
Elisabetta Rapiti
Anne-Francoise Allaz
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0826-9

Weitere Artikel der Ausgabe 3/2011

Supportive Care in Cancer 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.